Celgene Corporation
107.930.41 (0.38%)

After hours: 104.90-3.03 (-2.81%) as of 7:59 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close107.52
Bid104.66 x 100
Ask104.90 x 2200
52wk Range92.98 - 136.40
Day's Range106.73 - 108.14
Avg Vol (3m)4,368,698
As of 4:00 PM EDT. Market closed.
  • Investor's Business Daily10 hours ago

    Celgene Falls After Blockbuster Cancer Drug Revlimid Fails To Extend Survival

    Celgene won't seek approval for expanded use of Revlimid, which is approved in the U.S to treat multiple myeloma patients.

  • Reuters10 hours ago

    Celgene drug fails to extend survival in lymphoma study

    Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. As a result, the U.S. biotechnology company said it would not seek an additional approval for Revlimid for that use, and its shares fell more than 2 percent. Revlimid, a multiple myeloma treatment with annual sales of about $6 billion, was being tested versus a placebo in patients whose diffuse large B-cell lymphoma had responded to initial treatment with Roche's Rituxan and chemotherapy.